



Transanal Surgery for benign tumor or early rectal cancer: state of the art and future prospects of the surgeon

Guillaume Carrier, Philippe Rouanet

Department of Surgical Oncology, Montpellier Cancer Institute (ICM), Univ. Montpellier, Montpellier, France

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Pr Philippe Rouanet. Institut du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France.
Email: philippe.rouanet@icm.unicancer.fr.

Abstract: The Parks' procedure (1973) is the most recognized conventional transanal excision (TAE). A full-thickness en-bloc excision allows an entire resection of the rectal wall with a good pathologic staging. Buess et al. published in 1988 an innovative transanal endoscopic microsurgery (TEM) allowing access to larger and higher tumors. The initial results were very encouraging with a low complication rate of 5%. Compared to TAE, this technique has proven its superiority in terms of negative resection margin, fragmentation of the specimen, postoperative morbidity and local recurrence rate. Indications are now well established. The issue is mainly based on the risk of lymph node involvement that is in particular directly related to the depth of invasion but also to others poor pathologic features. The endoscopic mucosal resection (EMR) seems to be inferior to the TEM due to a piecemeal resection and a partial staging. However the endoscopic submucosal dissection (ESD) competes with surgical techniques, especially for tumors larger than 2 cm. To date there is no recommendation in favor of ESD or TEM for the management of large benign rectal adenomas or early rectal cancer. The concept of organ preservation has emerged due to the high rate of morbi-mortality and to the functional consequences of major rectal surgery. Recent studies are trying to select good responders after neoadjuvant treatment that could benefit from a local excision. The oncologic results of recent trials such as GRECCAR II are promising with no difference in term of oncologic outcomes with the radical surgery group. But the problem remains the specific morbidity of the completion total mesorectal excision in case of poor pathologic features. A rigorous selection of patients and in particular according to the analysis of the tumor response is needed.

Keywords: Local excision; transanal endoscopic microsurgery (TEM); early rectal cancer; organ preservation; neoadjuvant chemoradiotherapy

Received: 17 February 2020. Accepted: 06 March 2020; Published: 20 January 2021.
doi: 10.21037/ales.2020.03.13

View this article at: <http://dx.doi.org/10.21037/ales.2020.03.13>

Introduction

Transanal surgery for rectal polyps and villous adenomas is a widely used surgical technique. Conventional transanal excision (TAE) is the most common technique, with excellent results in terms of morbidity but also recurrence rate, known as Parks' procedure (1). Technical advances have made it possible to develop new devices that facilitate surgery and that allow local excision for larger tumors and

more difficult to access. For example, transanal endoscopic operation (TEO) described by Buess *et al.* at the end of the eighties (2) offers the advantage of better visibility and better exposure.

The most used endoscopic technique, the endoscopic mucosal resection (EMR) raises the question of a piecemeal resection without a good staging. Endoscopic submucosal dissection (ESD) is an emerging endoscopic technique that

could have comparable results to transanal surgery. The lack of comparative studies leaves the debate open.

Classically, Transanal surgery was done for early rectal tumors, the important morbi-mortality rate of radical rectal surgery and impairment of quality of life led the surgeon to reconsider management and to adapt neoadjuvant strategy in order to transform major surgery in tumorectomy. Transanal endoscopic surgery could be a preferred option in selected cases.

This review describes the different procedures to perform a transanal surgery, in comparison with endoscopic techniques, and discuss indications: benign tumor including large villous polyps, early rectal cancer. We also present the concept of organ preservation in rectal cancers after neoadjuvant chemoradiotherapy and its surgical and oncologic results.

Transanal surgery: which operative technique?

Technical evolution and description of the procedures

Different technique have been described such as the Kraske (1885) transsacral approach (3,4) or the York-Mason (1977) transsphincteric technique (5) but conventional TAE of a rectal polyp or early rectal cancer is most often carried out according to the Parks' technique describing since 1973 a local excision through the anal canal (1). This technique is now well codified (6) and has long been the most used. TAE procedure consists in a full-thickness excision after locating the tumor using for example a Parks' retractor for exposition. A line is drawn all around the lesion using electrocautery, before starting the resection, to ensure a free margin of 1 cm. *En-bloc* full-thickness excision, exposing the fat, is a key point to ensure resection of the entire rectal wall for both staging and curative treatment. The main limit of the conventional TAE technique concerns highest tumors, inaccessible, generally located more than 7-8 cm from the anal verge.

Buess *et al.* published in 1988 an innovative transanal endoscopic microsurgery (TEM) technique to break free from the limits of the TAE and to avoid the invasive York-Mason approach (2). To perform TEM, a rectoscope is introduced for gas insufflation in the rectal cavity. TEM offers many advantages, with a magnified view to perform an *en-bloc* full-thickness excision. Specimen is then stretched and pinned on a cork plate for pathologic exam. The surgical outcomes of the first 140 patients were very encouraging with a low complication rate of 5% with only 1 (0.7%)

postoperative bleeding. Concerning oncologic outcomes, 12 patients had local resection only for a pT1 carcinoma and there was no local recurrence or tumour spread (7). Buess *et al.* was already describing the need for a learning curve for this difficult technique, with the implementation of a training program (8). In the original technique, Buess *et al.* suggested to close the defect with a continuous resorbable suture finished using a silver clip on the thread (2). But this point remains controversial as the defect is below the peritoneal reflexion. To date, only 2 randomized control trial (RCT) (9,10) and 5 retrospective comparative studies (11-15) compared outcomes according to the closure of the rectal wall. *Table 1* summarizes these results. There appears to be a trend towards closing the defect in terms of postoperative complications but the result was not confirmed in the RCTs. A recent meta-analysis found no significant difference about morbidity, postoperative infection, postoperative bleeding rate and reintervention rate (16). So the discussion about closing the rectal wall after TEM is still open and no recommendation could be made. A technical issue that could arise with TME and didn't exist with the TAE is the occurrence and management of peritoneal perforation, in 1.7% to 15% of cases (17-21), particularly for anterior and upper rectal tumors. However, this complication should not cause the technique to be discussed because its laparoscopic suture is feasible as showed by Mege *et al.*, without an increase in postoperative morbidity rate if diagnosis was made during the procedure (18).

Comparison of operative techniques

Compared to TAE, TEM has proven its superiority (*Table 2*). Comparatives studies found advantages for TEM in terms of negative resection margin, fragmentation of the specimen (no *en-bloc* resection), postoperative morbidity and local recurrence rate (22-25). Clancy *et al.* published a meta-analysis with these data (26). They also demonstrated the superiority of TEM for negative microscopic margin rate ($P<0.001$), specimen fragmentation rate ($P<0.001$) and recurrence ($P<0.001$).

Different devices are used to perform TEM, with a better visualization and precision than TAE. Buess *et al.* initially described a reusable rectoscope still in use today: TEO® platform (Karl Storz, Tuttlingen, Germany) (2). Several disposable materials also allow TEM through a single-incision laparoscopic surgery port, called Transanal mini-invasive surgery (TAMIS) (27). The two most commonly used are the single-incision assisted laparoscopic surgery

Table 1 Results of studies evaluating the defect closure after transanal excision

Publication (ref)	Population (n)	Method	Defect Closed (n)	Endpoint	Results if defect closed (%)	Results if defect open (%)	p
Brown, Surg Endosc 2017 (11)	341	Retrospective	236	30-day complications	8.5	19	0.003
Brown, Colorectal Dis 2019 (10)	50	RCT	28	Postoperative pain day 1 – 3 – 7	2.8 – 2.8 – 2.8	2.6 – 2.1 – 1.7	0.76 – 0.23 – 0.09
Chan, Surg Endosc 2019 (12)	297	Retrospective	183	Recurrence	9.3	21.3	0.003
Chan, Surg Endosc 2019 (12)	297	Retrospective	183	R1 rate	6	10	<0.001
Hahnloser, Colorectal Dis 2015 (13)	75	Retrospective	40	Postoperative complications	13	17	ns
Lee, Dis Colon Rectum 2018 (15)	220	Retrospective	110	30-day complications	12	15	0.432
Lee, Dis Colon Rectum 2018 (15)	220	Retrospective	110	Postoperative bleeding	3	9	0.045
Noura, Mol Clin Oncol 2016 (14)	43	Retrospective	21	Postoperative complications	33.3	4.5	0.02
Ramirez, Colorectal Dis 2002 (9)	40	RCT	21	Postoperative bleeding	4.8	10.5	ns

Table 2 Results of comparative studies evaluating outcomes of TAE and TEM

Publication (ref)	R1 (%)			Specimen Fragmentation (%)			LR (%)			Complication (%)		
	TAE	TEM	P	TAE	TEM	P	TAE	TEM	P	TAE	TEM	P
Christoforidis, Ann Surg 2009 (22)	16	2	0.017	–	–	–	29.1	15.4	0.108	22	29	0.414
de Graaf, Colorectal Dis 2011 (23)	50	12	<0.001	23.8	1.4	<0.001	28.7	6.1	<0.001	10	5.3	<0.001
Han, World J Surg 2017 (24)	13.9	4.2	0.039	9.7	1.4	0.029	5.6	0	0.243	11.1	8.3	0.39
Moore, Dis Colon Rectum 2008 (25)	29	10	0.001	35	6	<0.001	24	4	0.004	17	15	0.69

TAE, transanal excision; TEM, transanal endoscopic microsurgery; R1, positive microscopic margins; LR, local recurrence.

(SILS) Port (Covidien, United States) and the GelPOINT Path Transanal Access Platform (Applied Medical, United States). There is no recommendation for preferential use of any of the devices. None of the techniques have proven to be superior for the quality of the surgical resection (21,28). TEO and TAMIS seem feasible depending on the surgeon's habits. Indeed, these surgical techniques require

rigorous learning curve to achieve quality oncologic results, in particular the rate of positive margin (R1). Lee *et al.* published an observational cohort studies showing that TAMIS requires a minimum of 14–24 cases to reach an acceptable R1 resection rate (29).

Technical and material advances have made it possible to increase the feasibility of transanal surgery.

Transanal surgery for benign tumor or early rectal cancer

Rectal polyps and villous tumors

Some indications of transanal surgery for rectal tumors are now well established. Concerning benign tumors, TEM has the advantage of a full-thickness resection compared with EMR, which generally performs a piecemeal resection, especially for large villous tumors that have an important risk of malignant transformation (30), up to 33% of unsuspected cancer for giant villous adenomas of the rectum (31). The difficulty in these cases of large villous tumors remains the preoperative evaluation even with careful clinical examination and MRI. For benign adenomas and villous tumors, TEM achieve a complete staging contrary to the EMR, with good surgical and oncologic outcomes. A large Italian multicentric cohort of 588 patients with benign tumor reported a global morbidity rate of 11.4%, no postoperative mortality, a percentage of local recurrence of 4.3% with a median operative time of 105 min (32). Concerning villous tumors, Pigot *et al.*, in a French series of 207 consecutive patients with large rectal villous adenomas (mean size of resected tumor: 5.4 cm), showed excellent results with a recurrent rate of 3.6% with a mean follow-up of 74 months. They noticed that specific recurrence-free probability was 99.5 percent at one year, 96 percent at five years, and 95 percent at ten years. (30).

Primary surgery for early rectal cancer

Management of early rectal cancer that can be discovered on the pathologic report or diagnosed at the beginning of treatment must take into account many parameters in particular the risk of lymph node involvement. Depth invasion of the rectal wall need to be described. The rate of lymph node involvement varies from 0 to 15% for T1 tumors and from 16 to 28% for T2 (33). Kikuchi classification for pT1 rectal adenocarcinoma consists in the division of the submucosal layer in three parts: sm1, sm2 and sm3 (34) with a lymph node involvement risk of 0–3% for sm1, 8–10% for sm2, and 23–25% for sm3 (35). The other additional risk factors increasing the rate of lymph node involvement that are details in the recent French Guidelines for the managements of rectal cancer are poor-differentiated tumors, vascular or lymphatic emboli and tumor budding (36–38). Bach *et al.* described a multivariable analysis to determine predictive factors of local recurrence: depth of invasion, diameter of the tumor and intramural lymphovascular

invasion (39). Tumor size and circumference are still debating (33) but are considered to be factors associated with technical difficulty as well as height (upper rectum) (19,40). Positive resection margin is usually considered as a pejorative factor but no study demonstrated the need to achieve a complete lymphadectomy instead of a new local excision (33,36).

A completion proctectomy with total mesorectal excision (cTME) should be discussed for patients with poor prognosis criteria due to lymph node involvement risk and local recurrence rate. In practice, local excision for T1sm1 without further risk factors is acceptable in term of nodal disease and local recurrence but a cTME should be discussed since there are associated risk factors or for T1sm2 or T1sm3 tumors.

Surgical outcomes after TEM for benign tumors or early rectal cancer (with no other treatment, excluding all neoadjuvant therapy) in large series are presented in Table 3 (20,32,39–44). Perioperative mortality is closed to 0 and major complication rate, which correspond to stages III–IV–V of the Dindo-Clavien classification (45), varies to a maximum of 3.8%.

With such good morbi-mortality results, it is difficult to envisage alternative management for these tumors. The TREND study was a retrospective analysis collecting data from patients treated with TEM or EMR for a large rectal adenoma (>2 cm). Early recurrence rate was 10.2% in the TEM group and 31.0% in the EMR group ($P<0.001$) (46).

Management of small rectal cancer: surgical resection or ESD?

ESD is an emerging endoscopic treatment, which competes with surgical techniques due to its proven superiority over the EMR in terms of *en-bloc* and curative resections and local recurrence rate, especially for tumors larger than 2 cm (47). Indeed, this technique allows mucosal and also sub-mucosal resection and avoids piecemeal resection contrary to EMR. But ESD is a complex procedure, responsible for a longer operative time (47). A debate has been developed between surgeons and endoscopists particularly with regard to the operative time, but also to the cost. The first retrospective study published by Park *et al.* in 2012 comparing ESD and TEM included adenomas with high grade dysplasia or early rectal cancer (T1) (48). *En-bloc* resection (96.7% *vs.* 100%, $P=0.476$) and R0 resection (96.7 *vs.* 97, $P=1$) rates did not differ between ESD group and TEM group respectively but procedure time for the

Table 3 Surgical outcomes after transanal surgery for benign tumor or early rectal cancer without any neoadjuvant treatment

Publication (ref)	Population (n)	Overall perioperative morbidity (%)	Minor complications (%)	Major complications (%)	Perioperative mortality (%)	Median (range) LOS (d)	Median (range) operative time (min)
Baatrup, Int J Colorectal Dis 2007 (41)	142	30.2	27.4	2.8	0.7	3 (2–36)	–
Bach, Br J Surg 2009 (39)	487	14.9	–	–	1.4	–	–
Guerrieri, Dig Liver Dis 2006 (32)	588	9.4	8.2	1.2	0	3.5	105
Khoury, Surg Endosc 2014 (40)	99	10	9	1	0	2 (1–17)	70 (35–240)
Kumar, Dis Colon Rectum 2013 (20)	325	10.5	–	–	0.3	0.54	119.5
Maleskar, Surg Endosc 2007 (42)	52	29.8	26	3.8	0	2 (1–12)	90 (20–150)
Ramirez, Ann Surg 2009 (43)	173	14.5	11	3.5	0.58	4 (2–30)	–
Said, Surg Endosc 1995 (44)	260	3.4	0	3.4	0.4	–	–

Minor complications, Dindo-Clavien I–II; Major complications, Dindo-Clavien III–IV–V; LOS, length of stay.

ESD group was shorter than that for the TEM group (mean: 84.0 min *vs.* 116.4 min, $P=0.023$). There were few patients in the study (only 30 ESD and 33 TEM). Kawaguti *et al.* published the second retrospective comparative study including 11 ESD and 13 TEM (49). There was no difference in the *en-bloc* resection rates with free margins: 81.8 % *vs.* 84.6 % ($P=0.40$) in ESD group and TEM group respectively. The operative time was also comparable ($P=0.69$). Finally a systematic review published by Arezzo *et al.* in 2014 with 21 series (but no comparative studies) for a total of 2,077 patients showed a higher *en-bloc* resection ($P<0.001$) and RO ($P<0.001$) rates in the benefit of TEM with no difference in the postoperative complications rate (50). So there is a clear lack of quality comparative studies on the subject and there is no consensus for the management of the large benign rectal adenomas or early rectal cancer. In this case, the European Association for Endoscopic Surgery (EAES) recommends that ESD and TEM are the two established techniques to perform local excision (51). A French prospective non-randomized study is in progress to compare ESD with TEM for early rectal cancer and rectal adenomas for R0 resection rate and the cost-effectiveness ratio: MUCEM-GRECCAR 13 (ClinicalTrials.gov Identifier: NCT02885142).

Transanal surgery for rectal cancer following neoadjuvant treatment

Rational

Radical surgery for rectal cancer is based on total

mesorectal excision (TME) (52). This management is well codified by oncologic quality criteria (36) but presents some challenges for the surgeon and the patient. First, sphincter preservation is a major issue that could be difficult for ultra-low rectal tumors. Even when sphincter preservation is possible, functional outcomes could be altered, in particular anal continence, by factors such as the type of anastomosis or the height of the tumor and so the height of the anastomosis (53). Sexual and urinary dysfunctions are also major complications for the patient, often underestimated, becoming more and more of a quality of life concern with an increasing number of studies evaluating prevalence, risk factors and management (54). The third key point for the discussion concerns anastomotic complications after TME. Pelvic abscess and anastomotic leakage rates remain high, up to 19% in large series (55–57). Locally advanced rectal cancer are treated first with neoadjuvant treatment (NAT): the reference is a chemoradiotherapy decreasing local recurrence rate (58,59). Tumor response after NAT need to be evaluated and it is a key point for surgical management. Pathologic complete response (pCR) rate after NAT and resection, which corresponds to pT0N0 tumors, ranges from 15 to 29% in recent RCTs (57,60,61).

So the concept of organ preservation has emerged (62): local excision after NAT is a treatment for residual N0 tumors (subcomplete or complete response) but it could be also a macrobiopsy to confirm staging and to adapt final management (63). It is now recognized that there is a correlation between the tumor response and the nodal status response (63). For pT0 and pT1 tumors, Rullier and Vendrely underlined that the 7% risk of positive lymph

Table 4 Results of studies evaluating outcomes of local excision following neoadjuvant treatment

Publication (ref)	Method	Population (n)	cTNM	pCR (%)	LRR n (%)	DR n (%)	Median follow-up (months)
Bujko, Radiother Oncol 2009 (65)	RCT	47	T1-3N0	41	3 (6.4)	1 (2.1)	14
Bujko, Radiother Oncol 2013 (66)	RCT	89	T1-3N0	43.8	13 (14.6)	6 (6.7)	24
Garcia-Aguilar, Lancet Oncol 2015 (69)	Prospective, Phase II	77	T2N0	44	3 (3.9)	5 (6.5)	56
Lezoche, Br J Surg 2012 (67)	RCT	50	T2N0	28	4 (8)	2 (4)	115
Perez, Dis Colon Rectum 2013 (70)	Retrospective	27	T2-3N0-1	11.1	4 (14.8)	5 (18.5)	15
Pericay, Clin Transl Oncol 2016 (71)	Prospective observational	15	T2-3N0	26.7	0 (0)	1 (6.7)	38
Pucciarelli, Dis Colon Rectum 2013 (72)	Prospective, Phase II	63	T2-3N0-1	30.2	2 (3.2)	3 (4.8)	36
Rullier, Lancet 2017 (64)	RCT	74	T2-3N0-1	–	4 (5.4)	9 (12.2)	36
Smart, Br J Sur 2016 (73)	Prospective	62	T1-2N0	32.3	4 (6.4)	4 (6.4)	13
Verseveld, Br J Surg 2015 (74)	Prospective	47	T1-3N0	44.7	4 (8.5)	1 (2.1)	17
Wawok, Radiother Oncol 2018 (68)	RCT	51	T1-3N0	47	11 (21.6)	6 (11.8)	104
TOTAL	–	602	–	–	52 (8.6)	43 (7.1)	–

cTNM, evaluation stage before NAT; pCR, pathologic complete response (=pT0); LRR, loco regional recurrence; DR, distant recurrence; RCT, randomized controlled trial.

nodes must be balanced with the 2% to 4% of operative morbidity in radical surgery for rectal cancer (63).

Oncologic results

Long-term oncologic results need to be discussed for patients treated with neoadjuvant chemoradiotherapy followed by local excision. The recent results of the French multicenter phase III RCT GRECCAR 2, comparing local excision and TME after neoadjuvant chemoradiotherapy in good responders, showed a 3-year loco-regional recurrence rate of 5.4% and 3-year distant recurrence rate of 12.2% in the local excision group in the intention-to-treat population. There was no difference between the groups in term of local recurrence, distant recurrence, disease-free survival and overall survival (64). Five RCTs (64-68) and 6 non-randomized studies (69-74), aiming to analysis oncologic outcomes in patients treated with local excision after NAT, are listed in *Table 4*. Loco-regional recurrence rate must be carefully analyzed according to the methods of the studies (for example when the analysis is retrospective). But the GRECCAR 2 (64), the American ACOSOG Z6041 (69) or the Italian multicenter phase II trial (72) found interesting results for selected patients (good responders after NAT or initially small tumors). It is also important to notice that pCR rate for small tumors treated with NAT

can reach 47%. Long-term results are presented in *Table 5*, in comparison to the few studies that report oncologic outcomes and long-term survival of local excision without any NAT, also in the case of benign tumors. Concerning studies evaluating long-term results after NAT, three-year disease-free survival varies from 78% to 91%, depending on the initial T and N of treated tumors, which is an acceptable oncologic outcome in these cases. In these papers, patients treated are good responders with a good oncologic prognosis. The other studies, with surgery first, usually include smaller tumors and present similar loco-regional recurrence rate and oncologic outcomes. The *Table 5* results support the possibility to perform local transanal surgery for certain well-selected rectal cancers after NAT (12,44,64,67,69,71,72,75,76).

Morbidity

Overall peri-operative morbidity rate following local excision after NAT ranges from 8.8% to 58.4% in different series (67,69,74,76-78). Very few studies have focused on the comparison of morbi-mortality rates with or without NAT. Marks *et al.*, in 2009, in a study with 62 patients, found an overall morbidity rate of 33% for the NAT group and 5.3% for the non-NAT group ($P<0.05$). The wound complication rate was also in favor of the non-NAT group

Table 5 Long term results of local excision with or without neoadjuvant treatment

Publication (ref)	Population (n)	NAT (n)	Cancer (%)	Benign (%)	R1 (%)	LRR (%)	3y-DFS (%)	5y-DFS (%)	3y-OS (%)	5y-OS (%)
Chan, Surg Endosc 2019 (12)	297	0	0	100	5.8	13.8	–	73.1	–	–
Garcia-Aguilar, Lancet Oncol 2015 (69)	77	77	100	0	1.3	4	88.2	79.3	94.8	90.3
Lezoche, Br J Surg 2012 (67)	50	50	100	0	0	8	–	88	–	80
Ondhia, Colorectal Dis 2019 (75)	141	–	33.3	66.7	8.5	4.7	–	82.9	–	87.9
Pericay, Clin Transl Oncol 2016 (71)	15	15	100	0	–	0	91	–	73	–
Pucciarelli, Dis Colon Rectum 2013 (72)	63	63	100	0	–	3.2	91	–	91.5	–
Rullier, Lancet 2017 (64)	74	74	100	0	0	5	78	–	92	–
Said, Surg Endosc 1995 (44)	260	0	0	100	–	6.5	–	93	–	–
Shin, Radiat Oncol J 2016 (76)	34	34	100	0	2.9	–	97.1	–	100	–

NAT, neoadjuvant treatment; DFS, disease-free survival; OS, overall survival.

($p=0.015$) (79). Two other studies reported results comparing morbidity rate with and without NAT: there was no significant difference (80,81).

The main problem for rectal cancer treated with local excision is the existence of poor prognostic factors requiring a cTME. Indeed, a second surgery in the early postoperative period exposes the surgeon to surgical difficulties due to inflammation and fibrosis, with a risk of increased anastomotic failure but also poorer oncologic outcomes. In the GRECCAR 2 trial, there was no superiority of local excision over TME because the primary endpoint was a composite outcome including morbi-mortality. The outcomes in the local excision group were more complicated due to the specific morbidity rate after cTME, concerning 38% of the cases. Major morbidity rates (Dindo III-IV) was 46% in patients treated with cTME, and only 12% in the local excision group without cTME and 22% in the TME group ($P=0.0031$) (64). Four case-matched studies and one retrospective cohort study have compared surgical, pathologic and oncologic outcomes between local excision plus cTME and primary TME (pTME) (82-86). Results are summarized in *Table 6*. There is a trend in favor of pTME in terms of overall morbidity (for example anastomotic complications), quality of mesorectal excision, definitive stoma and operative time. The second option after local excision following NAT with poor pathologic prognostic factors is a strict surveillance with salvage TME when a local regrowth or recurrence is diagnosed. However, here again TME seems to be associated with more R1 resection and local re-recurrences (87).

Local excision after NAT for rectal cancer is clearly feasible with increasingly controlled outcomes. But a rigorous selection of cases and in particular according to the analysis of the tumor response is needed. The tools for interpreting this response (MRI, biomarkers) are constantly being improved and will allow the surgeon to adapt the surgical strategy.

Conclusion and future prospects

Management of rectal cancer is in permanent evolution (88). The intensification of the neoadjuvant treatment, called Total Neoadjuvant Therapy (TNT) which used induction or consolidation chemotherapy could increase tumor response (with a higher rate of pCR) (89). This high rate of tumoral response should help surgeon to adapt the strategy in order to decrease surgical morbidity and to increase quality of life. A French prospective multicentric phase III randomized trial is in progress investigating this strategy (GRECCAR 12): the aim is to increase organ preservation in rectal cancer adding induction Folfirinox before chemoradiotherapy (ClinicalTrials.gov Identifier: NCT02514278).

Another approach to preserve the rectum consists in local excision followed by adjuvant treatment such as chemoradiotherapy in case of poor pathologic features. It could avoid cTME and it seems to be feasible oncologically for selected tumors. The risk-benefit balance with the morbidity of cTME should be taken into account (90-92). The TESAR trial is investigating this strategy and will try

Table 6 Comparative studies evaluating surgical, pathologic and oncologic outcomes after cTME and pTME

Publication (ref)	Method	cTME/ pTME (n)	Morbidity cTME/pTME (%)	Anast Compl cTME/pTME (%)	R1 cTME/ pTME (%)	Defect cTME/ pTME (%)	Definitive stoma cTME/ pTME (%)	LRR cTME/ pTME (%)	Operative time* (min) cTME/pTME	LOS* (day) cTME/pTME
Coton, Colorectal Dis 2019 (82)	Case-matched study	41/41	48.8/31.7	17/14.6	2,4/0	17/4.8	9.8/4.9	–	315 / 275*	14 / 13
Junginger, World J Surg Oncol 2019 (83)	Retrospective	46/–	–	–	–	–	–	6.5	–	–
Levic, Tech Coloproctol 2013 (84)	Case-matched study	25/25	52/52	4/4	–	40/14	56/56	0/8	165/193	10/10
Morino, Surg Endosc 2013 (85)	Case-matched study	17/34	11.8/23.5	–	0/0	0	41.2/11.7*	–	206 / 188*	10.9/11.1
Piessen, Colorectal Dis 2012 (86)	Case-matched study	14/25	64.3/32	42.8/8*	14.3/4	71/4*	28.6/28	–	305 / 279	14 / 14

*, Mean \pm SD or median (range). cTME, completion Total Mesorectal Excision; pTME, primary Total Mesorectal Excision; Defect (cTME or pTME), Incomplete mesorectal excision; LRR, loco regional recurrence.

to demonstrate the safety of adjuvant chemoradiotherapy after local excision (93).

In the near future, robotic devices could help local excision in selective difficult cases in particular within the limit of the TEM (94,95) but also with the help of a dedicated single port system (96).

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/ales.2020.03.13>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article

distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Parks AG, Stuart AE. The management of villous tumours of the large bowel. *Br J Surg* 1973;60:688-95.
2. Buess G, Kipfmüller K, Hack D, et al. Technique of transanal endoscopic microsurgery. *Surg Endosc* 1988;2:71-5.
3. Kraske P, Perry EG, Hinrichs B. A new translation of professor Dr P. Kraske's Zur Exstirpation Hochsitzender Mastdarmkrebse. 1885. *Aust N Z J Surg* 1989;59:421-4.
4. Meurette G. Description par Paul Kraske (1851-1930) en 1885 d'une voie d'abord périméale élargie emportant les dernières pièces sacrées pour accéder aux tumeurs du haut rectum : celle qui deviendra « la voie de Kraske ». *Côlon Rectum* 2019;13:161-2.

5. Mason AY. Transsphincteric approach to rectal lesions. *Surg Annu* 1977;9:171-94.
6. Nivatvongs S, Wolff BG. Technique of per anal excision for carcinoma of the low rectum. *World J Surg* 1992;16:447-50.
7. Buess G, Kipfmüller K, Ibal R, et al. Clinical results of transanal endoscopic microsurgery. *Surg Endosc* 1988;2:245-50.
8. Kipfmüller K, Buess G, Naruhn M, et al. Training program for transanal endoscopic microsurgery. *Surg Endosc* 1988;2:24-7.
9. Ramirez JM, Aguilera V, Arribas D, et al. Transanal full-thickness excision of rectal tumours: should the defect be sutured? a randomized controlled trial. *Colorectal Dis* 2002;4:51-5.
10. Brown CJ, Hochman D, Raval MJ, et al. A multi-centre randomized controlled trial of open vs closed management of the rectal defect after transanal endoscopic microsurgery. *Colorectal Dis* 2019;21:1025-31.
11. Brown C, Raval MJ, Phang PT, et al. The surgical defect after transanal endoscopic microsurgery: open versus closed management. *Surg Endosc* 2017;31:1078-82.
12. Chan T, Karimuddin AA, Raval MJ, et al. Predictors of rectal adenoma recurrence following transanal endoscopic surgery: a retrospective cohort study. *Surg Endosc* 2020;34:3398-407.
13. Hahnloser D, Cantero R, Salgado G, et al. Transanal minimal invasive surgery for rectal lesions: should the defect be closed? *Colorectal Dis* 2015;17:397-402.
14. Noura S, Ohue M, Miyoshi N, et al. Significance of defect closure following transanal local full-thickness excision of rectal malignant tumors. *Mol Clin Oncol* 2016;5:449-54.
15. Lee L, Althoff A, Edwards K, et al. Outcomes of Closed Versus Open Defects After Local Excision of Rectal Neoplasms: A Multi-institutional Matched Analysis. *Dis Colon Rectum* 2018;61:172-8.
16. Menahem B, Alves A, Morello R, et al. Should the rectal defect be closed following transanal local excision of rectal tumors? A systematic review and meta-analysis. *Tech Coloproctol* 2017;21:929-36.
17. Dafnis G, Pählman L, Raab Y, et al. Transanal endoscopic microsurgery: clinical and functional results. *Colorectal Dis* 2004;6:336-42.
18. Mege D, Petrucciani N, Maggiori L, et al. Peritoneal perforation is less a complication than an expected event during transanal endoscopic microsurgery: experience from 194 consecutive cases. *Tech Coloproctol* 2017;21:729-36.
19. Saget A, Maggiori L, Petrucciani N, et al. Is there a limit to transanal endoscopic surgery? A comparative study between standard and technically challenging indications among 168 consecutive patients. *Colorectal Dis* 2015;17:O155-60.
20. Kumar AS, Coralic J, Kelleher DC, et al. Complications of transanal endoscopic microsurgery are rare and minor: a single institution's analysis and comparison to existing data. *Dis Colon Rectum* 2013;56:295-300.
21. Lee L, Edwards K, Hunter IA, et al. Quality of Local Excision for Rectal Neoplasms Using Transanal Endoscopic Microsurgery Versus Transanal Minimally Invasive Surgery: A Multi-institutional Matched Analysis. *Dis Colon Rectum* 2017;60:928-35.
22. Christoforidis D, Cho HM, Dixon MR, et al. Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. *Ann Surg* 2009;249:776-82.
23. de Graaf EJR, Burger JWA, van Ijsseldijk ALA, et al. Transanal endoscopic microsurgery is superior to transanal excision of rectal adenomas. *Colorectal Dis* 2011;13:762-7.
24. Han J, Noh GT, Cheong C, et al. Transanal Endoscopic Operation Versus Conventional Transanal Excision for Rectal Tumors: Case-Matched Study with Propensity Score Matching. *World J Surg* 2017;41:2387-94.
25. Moore JS, Cataldo PA, Osler T, et al. Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. *Dis Colon Rectum* 2008;51:1026-30; discussion 1030-1031.
26. Clancy C, Burke JP, Albert MR, et al. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. *Dis Colon Rectum* 2015;58:254-61.
27. Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. *Surg Endosc* 2010;24:2200-5.
28. Mege D, Bridoux V, Maggiori L, et al. What is the best tool for transanal endoscopic microsurgery (TEM)? A case-matched study in 74 patients comparing a standard platform and a disposable material. *Int J Colorectal Dis* 2017;32:1041-5.
29. Lee L, Kelly J, Nassif GJ, et al. Establishing the learning curve of transanal minimally invasive surgery for local excision of rectal neoplasms. *Surg Endosc* 2018;32:1368-76.
30. Pigot F, Bouchard D, Mortaji M, et al. Local excision of large rectal villous adenomas: long-term results. *Dis Colon Rectum* 2003;46:1345-50.
31. Bains L, Lal P, Vindal A, et al. Giant villous adenoma of rectum- what is the malignant potential and what is the

- optimal treatment? A case and review of literature. *World J Surg Oncol* 2019;17:109.
32. Guerrieri M, Baldarelli M, Morino M, et al. Transanal endoscopic microsurgery in rectal adenomas: experience of six Italian centres. *Dig Liver Dis* 2006;38:202-7.
 33. Bretagnol F, Rullier E, George B, et al. Local therapy for rectal cancer: still controversial? *Dis Colon Rectum* 2007;50:523-33.
 34. Kikuchi R, Takano M, Takagi K, et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. *Dis Colon Rectum* 1995;38:1286-95.
 35. Verra M, Riente F, Arezzo A. Early rectal cancer treated by endoscopic submucosal dissection (ESD), endoscopic mucosal resection (EMR) or transanal endoscopic microsurgery (TEM). *Ann Laparosc Endosc Surg* 2018;3:67.
 36. Lakkis Z, Manceau G, Bridoux V, et al. Management of rectal cancer: the 2016 French guidelines. *Colorectal Dis* 2017;19:115-22.
 37. Beaton C, Twine CP, Williams GL, et al. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. *Colorectal Dis* 2013;15:788-97.
 38. Gérard JP, André T, Bibeau F, et al. Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). *Dig Liver Dis* 2017;49:359-67.
 39. Bach SP, Hill J, Monson JRT, et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. *Br J Surg* 2009;96:280-90.
 40. Khoury W, Igov I, Issa N, et al. Transanal endoscopic microsurgery for upper rectal tumors. *Surg Endosc* 2014;28:2066-71.
 41. Baatrup G, Elbrønd H, Hesselødt P, et al. Rectal adenocarcinoma and transanal endoscopic microsurgery. Diagnostic challenges, indications and short term results in 142 consecutive patients. *Int J Colorectal Dis* 2007;22:1347-52.
 42. Maslekar S, Pillinger SH, Monson JRT. Transanal endoscopic microsurgery for carcinoma of the rectum. *Surg Endosc* 2007;21:97-102.
 43. Ramirez JM, Aguilera V, Gracia JA, et al. Local full-thickness excision as first line treatment for sessile rectal adenomas: long-term results. *Ann Surg* 2009;249:225-8.
 44. Said S, Stippel D. Transanal endoscopic microsurgery in large, sessile adenomas of the rectum. A 10-year experience. *Surg Endosc* 1995;9:1106-12.
 45. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 2009;250:187-96.
 46. Barendse RM, van den Broek FJC, van Schooten J, et al. Endoscopic mucosal resection vs transanal endoscopic microsurgery for the treatment of large rectal adenomas. *Colorectal Dis* 2012;14:e191-6.
 47. Cao Y, Liao C, Tan A, et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. *Endoscopy* 2009;41:751-7.
 48. Park SU, Min YW, Shin JU, et al. Endoscopic submucosal dissection or transanal endoscopic microsurgery for nonpolypoid rectal high grade dysplasia and submucosa-invading rectal cancer. *Endoscopy* 2012;44:1031-6.
 49. Kawaguti FS, Nahas CSR, Marques CFS, et al. Endoscopic submucosal dissection versus transanal endoscopic microsurgery for the treatment of early rectal cancer. *Surg Endosc* 2014;28:1173-9.
 50. Arezzo A, Passera R, Saito Y, et al. Systematic review and meta-analysis of endoscopic submucosal dissection versus transanal endoscopic microsurgery for large noninvasive rectal lesions. *Surg Endosc* 2014;28:427-38.
 51. Morino M, Risio M, Bach S, et al. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. *Surg Endosc* 2015;29:755-73.
 52. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? *Br J Surg* 1982;69:613-6.
 53. Denost Q, Laurent C, Capdepon M, et al. Risk factors for fecal incontinence after intersphincteric resection for rectal cancer. *Dis Colon Rectum* 2011;54:963-8.
 54. Celentano V, Cohen R, Warusavitarne J, et al. Sexual dysfunction following rectal cancer surgery. *Int J Colorectal Dis* 2017;32:1523-30.
 55. Matthiessen P, Hallböök O, Rutegård J, et al. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. *Ann Surg* 2007;246:207-14.
 56. Denost Q, Rouanet P, Faucheron JL, et al. To Drain or Not to Drain Infraperitoneal Anastomosis After Rectal Excision for Cancer: The GRECCAR 5 Randomized Trial. *Ann Surg* 2017;265:474-80.
 57. Lefevre JH, Mineur L, Kotti S, et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial

- (GRECCAR-6). *J Clin Oncol* 2016;34:3773-80.
58. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731-40.
 59. van Gijn W, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncol* 2011;12:575-82.
 60. Akgun E, Caliskan C, Bozbiyik O, et al. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. *Br J Surg* 2018;105:1417-25.
 61. Terzi C, Bingul M, Arslan NC, et al. Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer. *Colorectal Dis* 2020;22:279-88.
 62. Rouanet P, Saint Aubert B, Fabre JM, et al. Conservative treatment for low rectal carcinoma by local excision with or without radiotherapy. *Br J Surg* 1993;80:1452-6.
 63. Rullier E, Vendrely V. Can mesorectal lymph node excision be avoided in rectal cancer surgery? *Colorectal Dis* 2011;13 Suppl 7:37-42.
 64. Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. *Lancet* 2017;390:469-79.
 65. Bujko K, Richter P, Kołodziejczyk M, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders. *Radiother Oncol* 2009;92:195-201.
 66. Bujko K, Richter P, Smith FM, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. *Radiother Oncol* 2013;106:198-205.
 67. Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. *Br J Surg* 2012;99:1211-8.
 68. Wawok P, Polkowski W, Richter P, et al. Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study. *Radiother Oncol* 2018;127:396-403.
 69. Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. *Lancet Oncol* 2015;16:1537-46.
 70. Perez RO, Habr-Gama A, Lynn PB, et al. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. *Dis Colon Rectum* 2013;56:6-13.
 71. Pericay C, Serra-Aracil X, Ocaña-Rojas J, et al. Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer. *Clin Transl Oncol* 2016;18:666-71.
 72. Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. *Dis Colon Rectum* 2013;56:1349-56.
 73. Smart CJ, Korsgen S, Hill J, et al. Multicentre study of short-course radiotherapy and transanal endoscopic microsurgery for early rectal cancer. *Br J Surg* 2016;103:1069-75.
 74. Verseveld M, de Graaf EJR, Verhoef C, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). *Br J Surg* 2015;102:853-60.
 75. Ondhia M, Tamvakeras P, O'Toole P, et al. Transanal endoscopic microsurgery for rectal lesions in a specialist regional early rectal cancer centre: the Mersey experience. *Colorectal Dis* 2019;21:1164-74.
 76. Shin YS, Yoon YS, Lim SB, et al. Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer. *Radiat Oncol J* 2016;34:177-85.
 77. Guerrieri M, Gesuita R, Ghiselli R, et al. Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. *World J Gastroenterol* 2014;20:9556-63.
 78. Stipa F, Picchio M, Burza A, et al. Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer. *Dis Colon Rectum* 2014;57:1245-52.
 79. Marks JH, Valsdottir EB, DeNittis A, et al. Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. *Surg Endosc* 2009;23:1081-7.
 80. Coco C, Rizzo G, Mattana C, et al. Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. *Surg Endosc* 2013;27:2860-7.
 81. Issa N, Murninkas A, Schmilovitz-Weiss H, et al. Transanal Endoscopic Microsurgery After Neoadjuvant

- Chemoradiotherapy for Rectal Cancer. *J Laparoendosc Adv Surg Tech A* 2015;25:617-24.
82. Coton C, Lefevre JH, Debove C, et al. Does transanal local resection increase morbidity for subsequent total mesorectal excision for early rectal cancer? *Colorectal Dis* 2019;21:15-22.
 83. Junginger T, Goenner U, Hitzler M, et al. Local excision followed by early radical surgery in rectal cancer: long-term outcome. *World J Surg Oncol* 2019;17:168.
 84. Levic K, Bulut O, Hesselheldt P, et al. The outcome of rectal cancer after early salvage TME following TEM compared with primary TME: a case-matched study. *Tech Coloproctol* 2013;17:397-403.
 85. Morino M, Allaix ME, Arolfo S, et al. Previous transanal endoscopic microsurgery for rectal cancer represents a risk factor for an increased abdominoperineal resection rate. *Surg Endosc* 2013;27:3315-21.
 86. Piessen G, Cabral C, Benoist S, et al. Previous transanal full-thickness excision increases the morbidity of radical resection for rectal cancer. *Colorectal Dis* 2012;14:445-52.
 87. Perez RO, Habr-Gama A, São Julião GP, et al. Transanal Endoscopic Microsurgery (TEM) Following Neoadjuvant Chemoradiation for Rectal Cancer: Outcomes of Salvage Resection for Local Recurrence. *Ann Surg Oncol* 2016;23:1143-8.
 88. Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. *J Clin Oncol* 2015 ;33:1797-808.
 89. Petrelli F, Trevisan F, Cabiddu M, et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. *Ann Surg* 2020;271:440-8.
 90. Sasaki T, Ito Y, Ohue M, et al. Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial. *Dis Colon Rectum* 2017;60:914-21.
 91. Borstlap WA, Coeymans TJ, Tanis PJ, et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. *Br J Surg* 2016;103:1105-16.
 92. Jeong JU, Nam TK, Kim HR, et al. Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer. *Radiat Oncol* 2016;11:114.
 93. Borstlap WA, Tanis PJ, Koedam TWA, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. *BMC Cancer* 2016;16:513.
 94. Warren CD, Hamilton AER, Stevenson ARL. Robotic transanal minimally invasive surgery (TAMIS) for local excision of rectal lesions with the da Vinci Xi (dVXi): technical considerations and video vignette. *Tech Coloproctol* 2018;22:529-33.
 95. Shuck RL, Larach SW, Atallah S. Robotic TAMIS for local excision of ultra-distal neoplasia. *Tech Coloproctol* 2019;23:395.
 96. Marks J, Ng S, Mak T. Robotic transanal surgery (RTAS) with utilization of a next-generation single-port system: a cadaveric feasibility study. *Tech Coloproctol* 2017;21:541-5.

doi: 10.21037/ales.2020.03.13

Cite this article as: Carrier G, Rouanet P. Transanal Surgery for benign tumor or early rectal cancer: state of the art and future prospects of the surgeon. *Ann Laparosc Endosc Surg* 2021;6:6.